Alcami completes site investment and expansion in drug product manufacturing and development facilities
Company has invested in semi-automated vacuum stopper equipment to generate prefilled syringe samples that can be used to screen and select components, complete compatibility studies, and conduct developmental stability studies.
Alcami has announced additional laboratory-scale capabilities to support prefilled syringes in Wilmington, NC and the successful completion of investments in Charleston, SC.
Alcami has invested in state-of-the-art, semi-automated vacuum stopper equipment in Wilmington, NC, to generate prefilled syringe samples that can be used to screen and select components, complete compatibility studies, and conduct developmental stability studies. With this equipment, Alcami can generate bench/pilot scale representative samples, minimizing the amount of API required to generate this critical data.
In addition, the company's clinical and commercial manufacturing facility in Charleston, SC has successfully produced clinical supply from its recently qualified second line with commercial manufacturing to follow. Coupled with the existing fill line, the site has doubled its filling capacity in 2016. A new, mid-scale lyophilization unit is being qualified, doubling the site's lyophilization capacity. To complement the additional equipment capacity, a third shift has been created, further adding capacity and scheduling flexibility with operations running 24 hours a day, five days a week.
"It is exciting to see the successful completion of recent investments that have enabled the doubling of our filling and lyophilization capacity at our Charleston site, and the extension of our development capabilities into pre-filled syringes. The site has introduced 17 new programs this year and is geared to support increasing demand within the Pharma & Biotech industry for sterile drug product development and manufacturing," stated Ted Dolan, Chief Operating Officer.
The Charleston, SC facility recently completed an FDA General Inspection that resulted in zero 483 observations as well as a successful EMA inspection supporting multiple commercial products. These results demonstrate Alcami's ongoing commitment to quality and regulatory compliance. Alcami's sterile manufacturing facility has a long-standing track record of compliance supporting numerous clinical and commercial regulatory filings globally.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.